Publication:
Cross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroon

Simple item page
dc.contributor.authorSwati B. Guptaen_US
dc.contributor.authorChristopher T. Masten_US
dc.contributor.authorNathan D. Wolfeen_US
dc.contributor.authorVlad Novitskyen_US
dc.contributor.authorSheri A. Dubeyen_US
dc.contributor.authorEsper G. Kallasen_US
dc.contributor.authorMauro Schechteren_US
dc.contributor.authorBernard Mbeween_US
dc.contributor.authorEftyhia Vardasen_US
dc.contributor.authorPunee Pitisuttithumen_US
dc.contributor.authorDonald Burkeen_US
dc.contributor.authorDan Freeden_US
dc.contributor.authorRobin Moggen_US
dc.contributor.authorPaul M. Coplanen_US
dc.contributor.authorJon H. Condraen_US
dc.contributor.authorRomnie S. Longen_US
dc.contributor.authorKiersten Andersonen_US
dc.contributor.authorDanilo R. Casimiroen_US
dc.contributor.authorJohn W. Shiveren_US
dc.contributor.authorWalter L. Strausen_US
dc.contributor.otherMerck & Co., Inc.en_US
dc.contributor.otherJohns Hopkins Bloomberg School of Public Healthen_US
dc.contributor.otherHarvard School of Public Healthen_US
dc.contributor.otherUniversidade Federal de Sao Pauloen_US
dc.contributor.otherUniversidade Federal do Rio de Janeiroen_US
dc.contributor.otherMalawi College of Medicineen_US
dc.contributor.otherMinistry of Population and Healthen_US
dc.contributor.otherUniversity of Witwatersranden_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherIntl. Partnership for Microbicidesen_US
dc.contributor.otherMerck Research Laboratoriesen_US
dc.date.accessioned2018-08-20T07:16:43Z
dc.date.available2018-08-20T07:16:43Z
dc.date.issued2006-06-01en_US
dc.description.abstractAn effective HIV type 1 (HIV-1) vaccine will likely require elicitation of broadly reactive cell-mediated immune (CMI) responses against divergent HIV-1 clades. We compared anti-HIV-1 T-cell immune responses among 363 unvaccinated adults infected with diverse HIV-1 clades. Response rates to clade B Gag and/or clade B Nef in Botswana (95%) and Cameroon (98%) were similar when compared with those in countries previously studied, including Brazil (92%), Thailand (96%), South Africa (96%), Malawi (100%), and the United States (100%). Substantial cross-clade cell-mediated immune responses in Botswana and Cameroon confirm previous findings in a larger, more genetically diverse collection of HIV-1 samples. Copyright © 2006 by Lippincott Williams & Wilkins.en_US
dc.identifier.citationJournal of Acquired Immune Deficiency Syndromes. Vol.42, No.2 (2006), 135-139en_US
dc.identifier.doi10.1097/01.qai.0000223017.01568.e7en_US
dc.identifier.issn15254135en_US
dc.identifier.other2-s2.0-33745092368en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/23745
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33745092368&origin=inwarden_US
dc.subjectMedicineen_US
dc.titleCross-clade reactivity of HIV-1-specific T-cell responses in HIV-1-infected individuals from Botswana and Cameroonen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33745092368&origin=inwarden_US

Files

Collections

Scopus 2006-2010